Dosing and uses of Latisse, Lumigan (bimatoprost)
Adult dosage forms and strengths
ophthalmic solution
- 0.01%
- 0.03%
Elevated Intraocular Pressure
Lumigan (0.01% or 0.03%): 1 gtt in affected eye qDay in evening
Hypotrichosis of the Eyelashes
Latisse (0.03%): 1 gtt on disposable sterile applicator & apply evenly along skin of upper eyelid margin at base of eyelashes
Pediatric dosage forms and strengths
Safety & efficacy not established
Latisse, Lumigan (bimatoprost) adverse (side) effects
>10%
Conjunctival hyperemia (25-45%)
Growth of eyelashes (15-45%)
Ocular pruritus (15-45%)
1-10%
Ocular dryness (3-10%)
Visual disturbance (3-10%)
Ocular burning (3-10%)
Foreign body sensation (3-10%)
Ocular pain (3-10%)
Pigmentation of the periocular skin (3-10%)
Blepharitis (3-10%)
Cataract (3-10%)
Superficial punctate keratitis (3-10%)
Eyelid erythema (3-10%)
Ocular irritation (3-10%)
Eyelash darkening (3-10%)
Ocular discharge (1-3%)
Tearing (1-3%)
Photophobia (1-3%)
Allergic conjunctivitis (1-3%)
Asthenopia (1-3%)
Increases in iris pigmentation (1-3%)
Conjunctival edema (1-3%)
Frequency not defined
Periorbital erythema
Eye swelling
Eyelids: burning sensation, edema, irritation, pruritus
Iris hyperpigmentation
Lacrimation increased
Madarosis and trichorrhexis
Periorbital and lid changes associated with a deepening of the eyelid sulcus
Rash (including macular, erythematous, and pruritic limited to the eyelids and periorbital region)
Skin discoloration (periorbital)
Blurred vision
Warnings
Contraindications
Hypersensitivity
Cautions
Caution with aphakic and pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
Contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses
Caution in active intraocular inflammation (e.g., uveitis)
Take soft contact lenses out when applying, reinsert at least 15 min later
Bacterial keratitis may result from inadvertent contamination of multi-dose ophthalmic solutions
May permanently change brown pigmentation of the iris, eyelid skin, and eyelashes
Not recommended for patients <16 years
Pregnancy and lactation
Pregnancy category: C
Lactation: Excretion in milk unknown; use with caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Latisse, Lumigan (bimatoprost)
Mechanism of action
Prostaglandin analog; increases outflow of aqueous humor
Pharmacokinetics
Absorption: No significant systemic accumulation
Half Life: 45 min
Peak plasma time: ≤10 min
Onset of action: 4hr (IOP reduction)
Peak effect: 8-12hr
Protein binding: 88%
Vd: 0.67 L/kg
Metabolism: Oxydation; N-deethylation and glucoronidation
Excretion: Urine (67%); feces (25%)
